UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000006423
Receipt number R000007625
Scientific Title The clinical trial to assess efficacy of mexiletine for amyotrophic lateral sclerosis
Date of disclosure of the study information 2011/10/01
Last modified on 2015/11/08 12:18:02

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The clinical trial to assess efficacy of mexiletine for amyotrophic lateral sclerosis

Acronym

Mexiletine on amyotrophic lateral sclerosis

Scientific Title

The clinical trial to assess efficacy of mexiletine for amyotrophic lateral sclerosis

Scientific Title:Acronym

Mexiletine on amyotrophic lateral sclerosis

Region

Japan


Condition

Condition

amyotrophic lateral sclerosis

Classification by specialty

Neurology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To assess the efficacy of mexiletine for amyotrophic lateral sclerosis

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

The reduction of ALS Functional Rating Scale Revised

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit


Blinding

Open -but assessor(s) are blinded

Control

Active

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

administration of mexiletine and riluzole

Interventions/Control_2

administration of riluzole only

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1)Over 20 years old.
2)Patient had probable or definite ALS disease, as defined in the Awaji electrophysiological criteria.
3)Subjects provided informed consent.

Key exclusion criteria

1)Patient did not have ability to comprehend informed consent
2)Patient had uncompensated medical illness
3)Patient had cardiac disease (myocardial infarction, valvular disease and cardiomyopathy etc.)
4)Patient had arrhythmia (incomplet AV-block and bundle branch block etc.)
5)Significant sinus bradycardia 6)Hypotension
7)Hypokalemia
8)Patient already administered anti-arrhythmic drug
9)Woman is pregnant or is breast-feeding
10)Subjects had forced vital capacity of< 60% predicted
11)Subjects were not allowed to take any other experimental agents 3 months before.
12)Subjects had concomitant disease effects peripheral nerve (diabetic peripheral neuropathy, hyperglycemia, ypercapnia etc.)
13)Not evoled CMAP amplitude in median nerve
14)Patient already performed tracheotomy or tube feeding.
15)Patient with disease duration of less than 36 months at study entry.
16)Patient had family history of amyotorphic lateral sclerosis.
17)Patient already administered other drug (procaine amide, quinidine, aprindine, amoxapine, antiepileptic drug). If patient suspend the administration of these drugs, they had possibility to exacerbate illness.

Target sample size

60


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Satoshi Kuwabara

Organization

Graduate School of Medicine, Chiba University, Japan.

Division name

Department of Neurology

Zip code


Address

1-8-1 Inohana, Chuo-ku, Chiba, 260-8670, Japan

TEL

0432262129

Email

kuwabara-s@faculty.chiba-u.jp


Public contact

Name of contact person

1st name
Middle name
Last name Kazumoto Shibuya

Organization

Graduate School of Medicine, Chiba University, Japan.

Division name

Department of Neurology

Zip code


Address

1-8-1 Inohana, Chuo-ku, Chiba, 260-8670, Japan

TEL

0432262129

Homepage URL


Email

kazumoto@net.email.ne.jp


Sponsor or person

Institute

Department of Neurology, Graduate School of Medicine, Chiba University, Japan.

Institute

Department

Personal name



Funding Source

Organization

none

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2011 Year 10 Month 01 Day


Related information

URL releasing protocol


Publication of results

Published


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2011 Year 09 Month 20 Day

Date of IRB


Anticipated trial start date

2011 Year 10 Month 01 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2011 Year 09 Month 28 Day

Last modified on

2015 Year 11 Month 08 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000007625


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name